c-Jun Antibody - #AF6090

(20)   (22)  
製品: c-Jun Antibody
カタログ: AF6090
タンパク質の説明: Rabbit polyclonal antibody to c-Jun
アプリケーション: WB IHC IF/ICC IP
反応性: Human, Mouse, Rat
予測: Pig, Zebrafish, Bovine, Rabbit, Dog, Chicken, Xenopus
分子量: 37kDa; 36kD(Calculated).
ユニプロット: P05412
RRID: AB_2834984

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200, IP, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Pig(100%), Zebrafish(100%), Bovine(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
クローナリティ:
Polyclonal
特異性:
c-Jun Antibody detects endogenous levels of total c-Jun.
RRID:
AB_2834984
引用形式: Affinity Biosciences Cat# AF6090, RRID:AB_2834984.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

Activator protein 1; AP 1; AP1; cJun; Enhancer Binding Protein AP1; Jun Activation Domain Binding Protein; JUN; Jun oncogene; JUN protein; Jun proto oncogene; JUN_HUMAN; JUNC; Oncogene JUN; p39; Proto oncogene c jun; Proto oncogene cJun; Proto-oncogene c-jun; Transcription Factor AP 1; Transcription factor AP-1; Transcription Factor AP1; V jun avian sarcoma virus 17 oncogene homolog; V jun sarcoma virus 17 oncogene homolog (avian); V jun sarcoma virus 17 oncogene homolog; V-jun avian sarcoma virus 17 oncogene homolog; vJun Avian Sarcoma Virus 17 Oncogene Homolog;

免疫原

免疫原:
Uniprot:

P05412(JUN_HUMAN) >>Visit HPA database.

遺伝子(ID):
JUN(3725)
発現特異性:
P05412 JUN_HUMAN:

Expressed in the developing and adult prostate and prostate cancer cells.

タンパク質の説明:
This gene is the putative transforming gene of avian sarcoma virus 17. It encodes a protein which is highly similar to the viral protein, and which interacts directly with specific target DNA sequences to regulate gene expression.
タンパク質配列:
MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAELHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGALSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHVNSGCQLMLTQQLQTF

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Dog
100
Xenopus
100
Zebrafish
100
Chicken
100
Rabbit
100
Horse
0
Sheep
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P05412 基板として

Site PTM Type Enzyme
T2 Phosphorylation Q13177 (PAK2)
T8 Phosphorylation Q13177 (PAK2)
Y26 Phosphorylation P41240 (CSK)
S37 Phosphorylation
S48 Phosphorylation
K50 Acetylation
K50 Ubiquitination
K56 Sumoylation
S58 Phosphorylation
T62 Phosphorylation
S63 Phosphorylation P45983 (MAPK8) , P45984 (MAPK9) , P06493 (CDK1) , Q15139 (PRKD1) , Q96KB5 (PBK) , Q8TD08 (MAPK15) , Q9H4B4 (PLK3) , P53779 (MAPK10) , Q00526 (CDK3) , P27361 (MAPK3) , Q99986 (VRK1)
K70 Ubiquitination
S73 Phosphorylation Q8TD08 (MAPK15) , P53779 (MAPK10) , Q99986 (VRK1) , P27361 (MAPK3) , P45983 (MAPK8) , Q96KB5 (PBK) , P06493 (CDK1) , Q9H4B4 (PLK3) , P45984 (MAPK9) , Q00526 (CDK3)
T89 Phosphorylation Q13177 (PAK2)
T91 Phosphorylation P45983 (MAPK8)
T93 Phosphorylation P45983 (MAPK8) , Q13177 (PAK2)
T95 Phosphorylation
T131 Phosphorylation
Y170 Phosphorylation P00519 (ABL1) , P41240 (CSK)
K226 Sumoylation
T231 Phosphorylation P68400 (CSNK2A1)
T239 Phosphorylation P49840 (GSK3A) , P49841 (GSK3B)
S243 Phosphorylation P06493 (CDK1) , P49841 (GSK3B) , P68400 (CSNK2A1) , Q92630 (DYRK2) , P49840 (GSK3A)
S249 Phosphorylation P68400 (CSNK2A1) , P78527 (PRKDC) , P49840 (GSK3A)
K254 Sumoylation
K268 Acetylation
C269 S-Nitrosylation
K271 Acetylation
K273 Acetylation
T286 Phosphorylation Q13177 (PAK2)
K309 Ubiquitination
C320 S-Nitrosylation

研究背景

機能:

Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. Binds to the USP28 promoter in colorectal cancer (CRC) cells.

PTMs:

Ubiquitinated by the SCF(FBXW7), leading to its degradation. Ubiquitination takes place following phosphorylation, that promotes interaction with FBXW7.

Phosphorylated by CaMK4 and PRKDC; phosphorylation enhances the transcriptional activity. Phosphorylated by HIPK3. Phosphorylated by DYRK2 at Ser-243; this primes the protein for subsequent phosphorylation by GSK3B at Thr-239. Phosphorylated at Thr-239, Ser-243 and Ser-249 by GSK3B; phosphorylation reduces its ability to bind DNA. Phosphorylated by PAK2 at Thr-2, Thr-8, Thr-89, Thr-93 and Thr-286 thereby promoting JUN-mediated cell proliferation and transformation. Phosphorylated by PLK3 following hypoxia or UV irradiation, leading to increase DNA-binding activity.

Acetylated at Lys-271 by EP300.

細胞の位置付け:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed in the developing and adult prostate and prostate cancer cells.

サブユニット構造:

Heterodimer with either FOS or BATF3 or ATF7. The ATF7/JUN heterodimer is essential for ATF7 transactivation activity. Interacts with DSIPI; the interaction inhibits the binding of active AP1 to its target DNA (By similarity). Interacts with HIVEP3 and MYBBP1A (By similarity). Interacts with SP1, SPIB and TCF20. Interacts with COPS5; the interaction leads indirectly to its phosphorylation. Component of the SMAD3/SMAD4/JUN/FOS/complex which forms at the AP1 promoter site. The SMAD3/SMAD4 heterodimer acts synergistically with the JUN/FOS heterodimer to activate transcription in response to TGF-beta. Interacts (via its basic DNA binding and leucine zipper domains) with SMAD3 (via an N-terminal domain); the interaction is required for TGF-beta-mediated transactivation of the SMAD3/SMAD4/JUN/FOS/complex. Interacts with methylated RNF187. Binds to HIPK3. Interacts (when phosphorylated) with FBXW7. Found in a complex with PRR7 and FBXW7. Interacts with PRR7 and FBXW7; the interaction inhibits ubiquitination-mediated JUN degradation promoting its phosphorylation and transcriptional activity. Interacts with RBM39 (By similarity). Interacts with PAGE4.

タンパク質ファミリー:

Belongs to the bZIP family. Jun subfamily.

研究領域

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Substance dependence > Cocaine addiction.

· Human Diseases > Substance dependence > Amphetamine addiction.

· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.

· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Th1 and Th2 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

参考文献

1). M6A demethylase FTO-mediated downregulation of DACT1 mRNA stability promotes Wnt signaling to facilitate osteosarcoma progression. ONCOGENE, 2022 (PubMed: 35121825) [IF=8.0]
2). Higenamine alleviates allergic rhinitis by activating AKT1 and suppressing the EGFR/JAK2/c-JUN signaling. PHYTOMEDICINE, 2021 (PubMed: 33945919) [IF=7.9]

Application: WB    Species: Human    Sample: human nasal epithelial cell

Fig. 8. The effects of higenamine (HG) on potential targets in histamine-induced HNEpCs. (A-J) Levels of protein expression of AKT1, p-AKT1, EGFR, p-EGFR, c-Jun, p-c-Jun, iNOS, JAK2, and p-JAK2 were determined by Western blotting, β-actin was used as an internal control. Data are expressed as means ± SD of three experiments. ## p < 0.01, and # p < 0.05 compared with the control group. ** p < 0.01, and * p < 0.05 compared with the histamine group.
3). The effects of Radix Angelica Sinensis and Radix Hedysari ultrafiltration extract on X-irradiation-induced myocardial fibrosis in rats. BIOMEDICINE & PHARMACOTHERAPY, 2019 (PubMed: 30780109) [IF=7.5]

Application: WB    Species: rat    Sample: cardiac

Fig. 5.| Representative images of the protein levels of col1α, OPN, P-c-fos and P-c-jun in the three groups. A, The protein expression levels of col1α, OPN, P-c-fos and P-c-jun were significantly increased in the X-ray group. After treatment with RAS-RH, the expression of col1α, OPN and P-c-jun was slightly decreased.B, Relative protein expression levels were analyzed by Image-Pro Plus 6.0 (n = 3, *P < 0.05, **P < 0.01 vs. the control group; #P < 0.05, ##P < 0.01 vs. the RAS-RH + X-ray group).
4). A non-retinol retinoic acid receptor-γ (RAR-γ/NR1B3) selective agonist, tectorigenin, can effectively inhibit the ultraviolet A-induced skin damage. British journal of pharmacology, 2022 (PubMed: 35731978) [IF=7.3]
5). Gambogenic acid induces apoptosis and autophagy through ROS‐mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells. PHYTOTHERAPY RESEARCH, 2023 (PubMed: 36086867) [IF=7.2]
6). The protection of luteolin against diabetic cardiomyopathy in rats is related to reversing JNK-suppressed autophagy. Food & Function, 2023 (PubMed: 36852907) [IF=6.1]
7). CCDC88C, an O-GalNAc glycosylation substrate of GALNT6, drives breast cancer metastasis by promoting c-JUN-mediated CEMIP transcription. Cancer cell international, 2024 (PubMed: 38971758) [IF=5.8]

Application: WB    Species: Human    Sample: breast cancer cells

Fig. 4 CEMIP was identified as a downstream gene of CCDC88C. BT549 cells with stable expression of CCDC88C were used to perform mRNA-seq. A The volcano plot showed the DEGs in cells stably transfected with CCDC88C overexpression vectors when compared with cells stably transfected with ev. B GO enrichments analysis of the DEGs in cells stably transfected with CCDC88C overexpression vectors. C BT-549 cells with stable expression of CCDC88C were transfected with pAP1-Ta-luc and pRL-TK plasmids. After 48 h, the relative luciferase was measured. D Immunoblotting was used to detect the level of c-JUN phosphorylation at Ser 63 and Ser 73 and total c-JUN. E The Venn diagram showed the overlapping DEGs in breast cancer cells stably transfected with CCDC88C overexpression vectors and breast cancer cells transfected with siRNA targeting JUN (siJUN). The heatmap showed 12 overlapping DEG expressions in breast cancer cells stably transfected with CCDC88C overexpression vectors or ev and breast cancer cells transfected with si-JUN or sinc. F BT-549 cells with stable expression of CCDC88C were transiently transfected with siJUN. After 48 h, CEMIP mRNA was detected using qRT-PCR. (G, H) BT-549 cells with stable expression of CCDC88C were transiently transfected with siCEMIP. After 48 h, Cell migration and invasion were measured by wound healing assays (× 100 magnification) and transwell assays (× 100 magnification), respectively. Scale bar: 200 μm. Data are expressed as the mean ± SD. DEGs, differentially expressed genes. FC, fold change. Adj p, adjust p value. CCDC88C coiled-coil domain containing 88C. ev empty vectors. oe overexpression. GO gene ontology. BP biological process. CC cellular component. MF molecular function. JUN Jun proto-oncogene, AP-1 transcription factor subunit. siRNA small interfering RNA. sinc negative control siRNA. CEMIP cell migration-inducing and hyaluronan-binding protein.
8). Loperamide induces protective autophagy and apoptosis through the ROS/JNK signaling pathway in bladder cancer. Biochemical pharmacology, 2023 (PubMed: 37863323) [IF=5.8]
9). Emodin Attenuates Lipopolysaccharide-Induced Acute Liver Injury via Inhibiting the TLR4 Signaling Pathway in vitro and in vivo. Frontiers in Pharmacology, 2018 (PubMed: 30186181) [IF=5.6]

Application: WB    Species: mouse    Sample: RAW264.7cell

FIGURE 4 | Effect of emodin on TLR4 and downstream molecules after LPS stimulation. (A–C) The mRNA levels of TLR4, MyD88, TIRAP, IRF-5, TRAF-6, TRIF,IRF-3, AP-1, and NF–κB were detected by RT-PCR. (D) The protein levels of the above molecules were detected by western blotting. Data are shown as the mean ± SD. #P < 0.05 compared to the normal group. ∗P < 0.05, ∗∗P < 0.01 vs model group; MP < 0.05, MMP < 0.01 vs DEX group.
10). LINC00909 up-regulates pluripotency factors and promotes cancer stemness and metastasis in pancreatic ductal adenocarcinoma by targeting SMAD4. Biology direct, 2024 (PubMed: 38504385) [IF=5.5]
もっと読みます

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.